| Boston Science Publishing

Editor Name: Dr. Waldemar Debinski

Country: North Carolina

University: Wake Forest University Baptist Medical Center

Educational Qualification: Cancer Biology PhD

Designation: Professor, Cancer Biology

Department: Department of Cancer Biology

Biography:Â

Waldemar Debinski, MD, PhD, pioneers the use of targets in malignant brain tumor cells that are not present in normal brain to destroy them effectively and safely. With a broad range of experience in both basic science and preclinical models, he develops novel approaches to drug development and delivery and partners with industry for both therapeutic licensing and testing purposes.

Research Laboratory

Debinski Lab - Focusing on the identification of molecular markers/targets that are specific to brain tumors and are pharmaceutically tractable.

Educational Program Involvement

Cancer Biology PhDÂ

Program Research Interest: Cellular defense and metabolism, Aberrant signaling pathways in tumor cells, Cell growth and survival, Molecular cancer epidemiology, Gene-environment interactions, Cancer control

Molecular Genetics and Genomics PhD

Program Research Interest: Identification of genetic variants that contribute to complex disease, Gene-environment interactions, Epigenetics, Genetic epidemiology, Bioinformatics

Graduate Programs in Neuroscience

Program Research Interest: Addiction and Substance Abuse, Behavioral and Systems Neurobiology, Development and Plasticity, Molecular Neurobiology, Neurological Disease and Aging, Neuropharmacology, Sensory Neurobiology

Departments and Affiliations

â€¢ Brain Tumor Center of Excellence

â€¢ Cancer Biology

â€¢ Center for Genomics and Personalized Medicine Research

â€¢ Comprehensive Cancer Center

Full Biography: http://profiles.wakehealth.edu/display/Person/debinski

Publications:

1. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?. Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, Miller LD, Cramer CK, Lesser GJ, Strowd RE, Hinson WH, Mott RT, Johnson AJ, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Neuroradiology. 2018 Oct; 60(10):1043-1051.

2. Hypoxia-inducible factor 2a: a novel target in gliomas. Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB, Sarkaria JN, Lesser GJ, Strowd RE. Future Med Chem. 2018 09; 10(18):2227-2236.

3. P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. Mao C, Zhao Y, Li F, Li Z, Tian S, Debinski W, Ming X. J Control Release. 2018 Sep; 286:289-300.

4. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD. Am. J. Clin. Oncol. 2018 08; 41(8):813-819.

5. Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D'Agostino RB, Watabe K. Cancer Res. 2018 Aug; 78(15):4316-4330.